The Brazilian health regulator Anvisa approved Etcamah (camizestranto), a new oral medication for advanced or metastatic breast cancer, on September 21, 2026. The U.S. FDA had previously granted accelerated approval on September 4, 2026, according to Folha de S.Paulo.
The approval marks a significant shift in treatment for patients with hormone-driven breast cancer, offering a targeted approach to overcome resistance. Etcamah, developed by AstraZeneca, belongs to a class of drugs called selective estrogen receptor degraders (SERDs), which both block and degrade estrogen receptors in cancer cells. This dual mechanism disrupts the signaling pathways that fuel tumor growth, particularly in cases where traditional hormonal therapies fail due to ESR1 mutations, as outlined by Saúde Abril and gov.br.
Clinical Trial Evidence and Efficacy
Approval was based on the phase 3 Serena-6 trial, which enrolled 315 patients with ESR1-mutated ER+/HER2- breast cancer. Participants who switched to Etcamah after detecting the mutation saw a 56% reduction in the risk of disease progression or death compared to those continuing standard hormonal therapy. The median time without progression increased from 9.2 to 16 months, according to data from multiple sources including Folha de S.Paulo and Portal do Zacarias.
The drug is approved for use after at least six months of first-line endocrine therapy combined with a CDK4/6 inhibitor, provided there are no radiological or clinical signs of disease progression. This proactive approach—intervening at the molecular level before visible tumor growth—represents a strategic shift in oncology care, as noted by Saúde Abril and gov.br. The specific criteria for eligibility include ER+ status, HER2- status, and the presence of an ESR1 mutation, as outlined in gov.br’s resolution 3.645/2026.
Regulatory Context and Pricing
While Anvisa granted the registration, the final price will be determined by the CMED (Câmara de Regulação do Mercado de Medicamentos), a regulatory body responsible for setting drug reimbursement limits in Brazil. The approval does not automatically include the treatment in the SUS (Sistema Único de Saúde), the country’s public health system, according to Campograndenews and gov.br.
However, its availability in Brazil will depend on pricing negotiations and regulatory guidelines, as outlined by R7 and Portal do Zacarias.
Epidemiological Significance
Breast cancer remains the most frequently diagnosed cancer among women in Brazil, with an estimated 73.610 new cases annually between 2023 and 2025, according to Inca data cited by multiple sources. The new treatment addresses a critical gap in managing ER+/HER2- tumors, which account for a significant portion of these cases.
By targeting molecular changes in tumors, the drug offers a more tailored approach than traditional therapies, which often rely on broader, less specific interventions.
Next Steps and Uncertainties
The immediate next step is the CMED’s evaluation of the drug’s price, which will determine its accessibility. Meanwhile, healthcare providers will need to implement new protocols for detecting ESR1 mutations through liquid biopsies, as highlighted by Campograndenews and gov.br. The long-term effectiveness and safety profile of Etcamah will also require ongoing monitoring, as noted by R7 and O Povo.
For patients, the approval brings hope but also uncertainty about coverage and affordability. The coming months will reveal whether Brazil’s regulatory and healthcare systems can bridge the gap between innovation and patient access.